Sign in
DBTX Stock Price, Chart, Stats & News
Decibel Therapeutics, Inc.
Save
Decibel Therapeutics, Inc. (DBTX) does not currently pay a dividend.
123.37M
Market cap
–
Current P/E
–
Forward P/E
DBTX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.38% |
ROA | -51.07% |
ROE | -56.38% |
D/E | 0.17x |
Interest coverage ratio | -53.66x |
DBTX valuation
P/E | – |
P/S | – |
P/B | 1.50x |
P/CF | -2.15x |
P/FCF | -2.15x |
P/OCF | -2.15x |
PEG | -0.02x |
EV multiple | -2.39x |
About
Decibel Therapeutics, Inc. (DBTX) is a clinical-stage biotechnology firm dedicated to pioneering innovative therapies for a range of hearing and balance impairments. Their research and development efforts are concentrated across three primary therapeutic avenues: 1. Gene Therapies for Congenital, Monogenic Hearing Loss: These programs aim to re-establish functional cellular activity within the cochlea, thereby counteracting hearing deficiencies stemming from single gene mutations. 2.
Similar securities
Based on sector and market capitalization
Report issue